Journal of Cancer Research and Therapeutics Close
 

Figure 1: Checkpoint inhibition through PD-1 pathway puts brakes on tumor-specific immune response while PD-1 antibodies release those brakes. (a) Engagement of PD-L1 receptor on T cell with tumor cells or antigen presenting cells PDL-1/PDL-2 ligands leading to recruitment of phosphatase SRC Homology 2-Domain-Containing protein Tyrosine Phosphatase 2 (SHP-2) to PD-1, dephosphorylation of T-cell receptor signaling kinases by SHP-2 and subsequent T-cell energy or exhaustion. (b) Administration of PD-1 blocking agents such as nivolumab inhibits PD-1 and PDL-1/PDL-2 interactions and the events that put brakes on T cells from building an antigen-specific T-cell response

Figure 1: Checkpoint inhibition through PD-1 pathway puts brakes on tumor-specific immune response while PD-1 antibodies release those brakes. (a) Engagement of PD-L1 receptor on T cell with tumor cells or antigen presenting cells PDL-1/PDL-2 ligands leading to recruitment of phosphatase SRC Homology 2-Domain-Containing protein Tyrosine Phosphatase 2 (SHP-2) to PD-1, dephosphorylation of T-cell receptor signaling kinases by SHP-2 and subsequent T-cell energy or exhaustion. (b) Administration of PD-1 blocking agents such as nivolumab inhibits PD-1 and PDL-1/PDL-2 interactions and the events that put brakes on T cells from building an antigen-specific T-cell response